Literature DB >> 23661032

Puerarin-induced immune hemolytic anemia.

Fei Chen1, Shangqin Liu, Jiang Wu.   

Abstract

Drug-induced immune hemolytic anemia (DIIHA) is a relatively uncommon condition characterized by a sudden drop in hemoglobin, putatively following exposure to drugs. Severe forms of hemolysis characterized by rapidly falling hemoglobin levels and hemoglobinuria are extremely rare. Here we report the case of a patient who exhibited severe DIIHA due to puerarin. Direct antiglobulin testing and drug-dependent antibody testing indicated that the antibodies were drug-dependent and reacted only with RBCs in the presence of the drug. Puerarin is the major isoflavonoid derived from the Chinese medical herb Radix puerariae, and has not yet been widely reported as associated with DIIHA. These results suggest that puerarin may be a cause of severe hemolysis and should be used with caution.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 23661032     DOI: 10.1007/s12185-013-1357-1

Source DB:  PubMed          Journal:  Int J Hematol        ISSN: 0925-5710            Impact factor:   2.490


  6 in total

1.  Drug induced immune haemolytic anaemia in the Berlin Case-Control Surveillance Study.

Authors:  Edeltraut Garbe; Frank Andersohn; Elisabeth Bronder; Andreas Klimpel; Michael Thomae; Hubert Schrezenmeier; Martin Hildebrandt; Ernst Späth-Schwalbe; Andreas Grüneisen; Beate Mayer; Abdulgabar Salama; Hanife Kurtal
Journal:  Br J Haematol       Date:  2011-07-12       Impact factor: 6.998

Review 2.  Immune hemolytic anemia associated with drug therapy.

Authors:  George Garratty
Journal:  Blood Rev       Date:  2010-07-21       Impact factor: 8.250

3.  Role of the interaction between puerarin and the erythrocyte membrane in puerarin-induced hemolysis.

Authors:  Shao-Zhen Hou; Zi-Ren Su; Shu-Xian Chen; Mu-Rong Ye; Song Huang; Liang Liu; Hua Zhou; Xiao-Ping Lai
Journal:  Chem Biol Interact       Date:  2011-03-29       Impact factor: 5.192

4.  [Clinical analysis of 5 cases with acute intravascular hemolysis caused by puerarin].

Authors:  Bo Wang; Yu-Zhen Zhu; Xiu-Qing Li; Ya-Nan Tian; Hui Xiong; Xu-Yan Chen
Journal:  Beijing Da Xue Xue Bao Yi Xue Ban       Date:  2004-02

5.  [A clinical efficacy and safety study on coronary heart disease and angina treatment with Puerarin Injection].

Authors:  Zhi-kuan Luo; Yong Liu; Huan-ming Li
Journal:  Zhonghua Liu Xing Bing Xue Za Zhi       Date:  2012-06

6.  Opening the calcium-activated potassium channel participates in the cardioprotective effect of puerarin.

Authors:  Qin Gao; Bo Yang; Zhi-Guo Ye; Jue Wang; Iain C Bruce; Qiang Xia
Journal:  Eur J Pharmacol       Date:  2007-07-18       Impact factor: 4.432

  6 in total
  2 in total

1.  Pharmacovigilance in China: current situation, successes and challenges.

Authors:  Li Zhang; Lisa Y L Wong; Ying He; Ian C K Wong
Journal:  Drug Saf       Date:  2014-10       Impact factor: 5.606

2.  Puerarin inhibits proliferation and induces apoptosis in human glioblastoma cell lines.

Authors:  Ji-An Yang; Ji-Qiang Li; Ling-Min Shao; Qian Yang; Bao-Hui Liu; Ting-Feng Wu; Peng Wu; Wei Yi; Qian-Xue Chen
Journal:  Int J Clin Exp Med       Date:  2015-06-15
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.